Home > Oncology > ASCO 2022 > ATHENA-MONO: primary results of rucaparib in ovarian cancer

ATHENA-MONO: primary results of rucaparib in ovarian cancer

Presented By
Prof. Bradley Monk, University of Arizona, AZ, USA
ASCO 2022
Phase 3, ATHENA
First-line rucaparib maintenance therapy after platinum-based chemotherapy improved the progression-free survival of patients with stage III-IV ovarian cancer. Further tumour reductions were reported following treatment with rucaparib. The efficacy of the PARP inhibitor rucaparib has been established in patients with platinum-sensitive recurrent ovarian cancer [1]. Also, PARP inhibitors have delivered PFS benefits as first-line maintenance treatment [2]. However, the optimal first-line maintenance strategy for patients with advanced ovarian cancer is still unclear. The phase 3 ATHENA trial (NCT03522246) randomised patients with phase III or IV ovarian cancer, who responded to first-line platinum-based doublet chemotherapy, 4:4:1:1 to rucaparib plus nivolumab (arm A), rucaparib plus placebo (arm B), placebo plus nivolumab (arm C), and placebo plus placebo (a...

Please login to read the full text of the article.

If you have no account yet, please register now.

Posted on